Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors.
Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis—this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers.
Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year.
'This is a transformative milestone for Continuity Biosciences,' said Ramakrishna Venugopalan, PhD, MBA, Chief Executive Officer of Continuity Biosciences. 'Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic.'
Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill. In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms.
Visionary Founders Driving the Innovation
Focal Medical was co-founded by:
Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity.
'After nearly a decade of R&D, we are excited to join the Continuity Biosciences family,' said Tony Voiers, Acting CEO of Focal Medical. 'We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers.'
This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy.
About Continuity Biosciences
Continuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL; Houston, TX; Raleigh, NC; and Torino, Italy, the company focuses on combination drug-device platforms for chronic and complex conditions.
Visit: www.continuitybiosciences.com
About Focal Medical
Focal Medical, Inc. develops energy-based chemotherapy delivery systems that enable direct application of drugs to tumor sites. Its mission is to improve efficacy and reduce toxicity in the treatment of solid tumors, with an initial focus on pancreatic cancer.
Visit: www.focalmedical.co
View original content to download multimedia: https://www.prnewswire.com/news-releases/continuity-biosciences-acquires-focal-medical-to-advance-targeted-drug-delivery-for-pancreatic-cancer-302472112.html
SOURCE Continuity Biosciences LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
2 hours ago
- Time Business News
The Financial Backbone of Startups: Why Austin Entrepreneurs Need Professional CPA and CFO Support
Austin, Texas, continues to attract some of the most innovative minds and fastest-growing startups in the country. From tech ventures to local service-based businesses, the entrepreneurial spirit is thriving. Yet for all the excitement and energy, one challenge keeps tripping up promising ventures: financial mismanagement. Many entrepreneurs focus on product development, customer acquisition, and branding—leaving accounting, forecasting, and compliance as afterthoughts. But in a city where competition is fierce and investors are selective, overlooking your financial health can cost you growth—or even your business. The startup journey often comes with: Inconsistent revenue Unclear cash flow Poorly tracked expenses Tax surprises Missed funding opportunities Founders are typically visionaries, not financial experts. As a result, many operate their businesses using spreadsheets, gut instincts, or outdated accounting software. These approaches might work in the first few months—but not when you're scaling, hiring, or seeking capital. Before you bring in CFO-level leadership or consult with CPA firms, your first step should be hiring a small business accountant in Austin. Bookkeeping : Maintain organized and accurate records of all transactions. : Maintain organized and accurate records of all transactions. Payroll : Process employee payments and ensure tax withholdings are accurate. : Process employee payments and ensure tax withholdings are accurate. Monthly Statements : Help you understand profits, losses, and where your money goes. : Help you understand profits, losses, and where your money goes. Quarterly Taxes: Keep your business compliant and avoid IRS penalties. Because they're local, an Austin-based accountant understands Texas tax rules, franchise tax obligations, and local filing deadlines better than a remote service. Bonus: Many small business accountants now use cloud-based software, giving you 24/7 visibility into your finances and eliminating guesswork. Once you're generating consistent revenue or considering scaling, a small business accountant might not be enough. This is where CFO service in Austin TX comes in. A Chief Financial Officer (CFO) isn't just a number cruncher. They're a financial strategist who provides leadership on: Cash flow forecasting Financial modeling and budgeting Investor readiness Loan or funding management Expense optimization KPI tracking and performance evaluation By hiring outsourced CFO services in Austin, startups get executive-level financial support without paying full-time executive salaries. It's a powerful way to gain expert insight while staying lean. Here are some real-world examples of how CFO support makes a difference: A CFO helps you assess whether you can truly afford to expand your team or open a new office—or if waiting 6 months would save you from cash flow trouble. Without knowing your margins, it's easy to undercharge. A CFO will analyze your costs and recommend a sustainable pricing structure. If your books are messy, or your pitch deck lacks solid financials, investors will walk away. A CFO ensures you're always 'investor-ready.' By working closely with your accountant and eventually a CPA firm, a CFO keeps you organized year-round so you're not scrambling when April rolls around. Austin isn't just any city—it's a tech hub, creative powerhouse, and magnet for venture capital. When you partner with local financial professionals, you gain access to: Regional insights on Texas tax law and local compliance. on Texas tax law and local compliance. Networks that include bankers, investors, and startup mentors. that include bankers, investors, and startup mentors. Personalized service from people who understand your business context. Unlike generic national services, local financial professionals understand the Austin startup scene and can offer advice grounded in real-world experience. As your startup matures, your needs will expand beyond bookkeeping and strategy. You'll require compliance, audit prep, advanced tax strategy, and possibly even exit planning. That's where CPA firms in Austin play a critical role. Tax filing and planning (local, state, federal) (local, state, federal) Audit preparation and representation Business incorporation advice Entity restructuring for tax savings Compliance with industry-specific regulations Valuation support for mergers or acquisitions CPA firms don't just look backward at your finances—they help you plan for future moves and long-term goals. Stage of Business Financial Support Needed Pre-launch/Prototype Small business accountant Post-revenue (>$100K) Add CFO service Austin TX Scaling (>$500K+) Add CPA firms in Austin Hiring early doesn't mean overextending—it means preparing for growth from day one. Today's financial experts—especially in tech-forward Austin—rely on digital tools to streamline operations. From cloud-based bookkeeping to real-time dashboards, the best financial partners will integrate with your systems like: QuickBooks Online Xero Gusto (for payroll) Expensify Fathom or Spotlight for reporting By leveraging these platforms, you get real-time financial visibility that informs better business decisions. Whether you're considering a small business accountant, CFO service, or CPA firm, ask: What industries do you specialize in? Do you understand the startup and venture-backed landscape? How do you communicate and deliver reports? What's your fee structure? Do you offer scalable services as we grow? Can you collaborate with our other partners (legal, banking, etc.)? Your financial team should feel like an extension of your startup—not just a service provider. Building a startup is hard enough. Don't let poor financial decisions be the reason you fail. By working with a reliable small business accountant in Austin, engaging strategic CFO service in Austin TX, and eventually partnering with experienced CPA firms in Austin, you're putting the right financial backbone in place to support your growth, funding goals, and long-term success. Whether you're preparing for your next funding round, trying to control runaway costs, or aiming for a clean exit—having trusted financial leadership will guide every decision with clarity and confidence. TIME BUSINESS NEWS
Indianapolis Star
3 hours ago
- Indianapolis Star
FDA: More cucumbers, ready-to-eat products recalled in growing salmonella outbreak
A Maryland food company has recalled specific salsa and cucumber products because they were made with cucumbers that are possibly contaminated with salmonella. TGD Cuts, LLC of Jessup, Maryland, is recalling some tub and tray products because they contained cucumbers from Boynton Beach, Florida-based Bedner Growers Inc., which have been linked to a salmonella outbreak. TGD Cuts distributed the affected products, which included salsas, sliced cucumbers and cucumber spears, to retail and foodservice locations in Maryland, Virginia, Pennsylvania, New Jersey, and North Carolina, according to the Food and Drug Administration (FDA). The products had use-by dates ranging from May 20 to May 28 and are unlikely to be in stores or being used. No illnesses have been reported in connection with the products, the FDA said. Egg recall: Brown eggs sold at some Walmart stores have salmonella risk The initial May 19 recall involved cucumbers sold directly to consumers at Bednar's Farm Fresh Market, according to notices published May 19 by the Centers for Disease Control and Prevention (CDC) and the FDA. Subsequent recalls have been announced by grocers such as Harris Teeter, Kroger and Walmart for repackaged cucumbers for resale under different brand names or those used in ready-to-eat products, including vegetable trays and salads. The cucumbers, distributed by Fresh Start Produce Sales of Delray, Florida, also led to Target recalling individual cucumbers on May 30, specifically cucumber two-packs and various prepared foods products. In addition to the growing cucumber-related recall, other products have been recalled recently for potential salmonella contamination. The FDA on May 28 upgraded a recall of tomatoes distributed in three southern states to a Class I recall, meaning consumption of the food could cause serious health complications or lead to death. Then, on June 6, the CDC and FDA linked brown eggs sold in nine states – including at some Walmart stores – to an ongoing Salmonella Enteritidis outbreak, in which 79 people have been sickened and at least 21 hospitalized. Customers who purchased any products from TGD Cuts should get rid of them or return them for a full refund. Here is the list of products recalled due to a possible salmonella risk. Salmonella poisoning causes about 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths each year in the U.S., according to the CDC and FDA. Symptoms, which include diarrhea, fever and stomach cramps, will usually occur six hours to six days after exposure and may last up to seven days. Symptoms from severe infections may include aches, headaches, elevated fever, lethargy, rashes, and blood in urine or stool. Mike Snider is a reporter on USA TODAY's Trending team. You can follow him on Threads, Bluesky, X and email him at mikegsnider & @ & @mikesnider & msnider@
San Francisco Chronicle
3 hours ago
- San Francisco Chronicle
New Alzheimer's blood tests make diagnosis easier — but they're not right for everyone
The number of Americans with Alzheimer's disease, the most common cause of dementia in the U.S., is projected to rise significantly in the coming decades. The devastating disease has no cure, but the past several years have brought promising developments in new drug therapies and blood tests that help doctors treat and diagnose the disease. Here's what to know about the blood tests that diagnose Alzheimer's, one of which got full FDA approval in May. How they work Several commercially available blood tests have become available the past few years, most recently from biotech company Fujirebio Diagnostics, which got full approval from the FDA last month. Each test measures slightly different things, but overall they look for abnormal levels of certain proteins — amyloid and tau — in the blood. The accumulation of amyloid and tau proteins in the brain, often called plaques, are hallmark signs of Alzheimer's. If someone has tau plaques in the brain, for instance, some of that will leak out of the brain into the blood, resulting in a blood test result showing higher than normal levels of tau. In patients with symptoms of cognitive impairment, the tests predict an Alzheimer's diagnosis with about 90% accuracy. Why they're important The blood tests are a notable development because they are less expensive and less invasive than other types of testing that doctors have long used to diagnose patients with Alzheimer's. One is a PET scan, which involves injecting a patient with a radioactive tracer that binds to amyloid or tau in the brain so the presence of the proteins can be seen in a scan. It can cost several thousand dollars, compared to several hundred dollars for a blood test. The other is a spinal tap, which is painful or uncomfortable for many people. This method measures different forms of amyloid and tau in the spinal fluid. 'Up until these blood tests came out, a physician was stuck doing a PET scan or spinal tap, so not great options,' said Dr. Frank Longo, a professor of neurology at Stanford Medicine. 'The big breakthrough is finding something to measure in the blood that's about 90% accurate of what's going on in the brain, about as accurate as spinal fluid or a PET scan.' Doctors use the blood test as part of a broader medical evaluation that also includes a patient history, neurological exam and other testing. The blood test can help rule out Alzheimer's as the cause of a patient's cognitive impairment and potentially avoid unnecessary further testing. If someone's blood test comes back normal, for example, they may not have to undergo the PET scan or spinal tap, and their doctor can look into other potential causes of the cognitive impairment. 'That's the biggest practical thing it's doing now,' Longo said. It's important to distinguish Alzheimer's from other types of dementia because there are Alzheimer's treatments that have come out the last few years that help slow the progression of Alzheimer's. But patients must be in relatively early stages of the disease, with mild impairment or mild dementia, to be eligible. Some of the therapies have significant side effects, so patients would not want to start them unless they knew it was Alzheimer's, and not something else, causing the dementia. They're not for everyone The tests are approved only for people who already have symptoms of cognitive impairment and are of a certain age — 55 and over or 60 and over, depending on the test. They are not approved for healthy adults with normal cognition who want to diagnose or rule out Alzheimer's, or who are simply curious if they are at risk for developing Alzheimer's. They must be ordered by a doctor. They're becoming more common, but may not be covered by insurance Some of the blood tests have been available for a year or two, Longo said, but they were under an earlier and more limited type of FDA approval, not the full approval that the agency granted last month to the Fujirebio test. So they are poised to become more common. 'A year ago, most of my colleagues and I were not ordering these,' Longo said. 'I'd say less than 5% or 10% of the time we were ordering these. Now people are starting to order them in symptomatic patients. It's not rare now. They're starting to be recognized more.' Some primary care doctors are starting to order the tests as well, said Dr. Armen Moughamian, medical director of Sutter Health's Ray Dolby Brain Center at CPMC in San Francisco. The center treats patients with memory disorders. 'It's definitely a minority, but I've been seeing it done,' he said. As with many new medical tests, insurers may not cover them yet, but that usually evolves over time. Full FDA approval may help make the case for the tests to be covered, Longo said. 'There is some uncertainty and lack of clarity about whether insurance and Medicare pay,' Moughamian said. 'That creates some hesitancy for providers to order it.' They may one day be used to screen and diagnose healthy people earlier In people with Alzheimer's, amyloid plaques begin to form in the brain as many as 20 years before they show symptoms. Right now, newer therapies for Alzheimer's — like lecanemab and donanemab, which slow the progression of the disease — are approved only for people with symptoms. Those symptoms are mild cognitive impairment or mild dementia, the early stages of symptomatic Alzheimer's. This means people who have not yet developed symptoms, but who have amyloid plaques in the brain, cannot get these treatments. So if a blood test could be used in pre-symptomatic people, it could mean better screening and earlier diagnosis to larger groups of people. 'What we want to push for is earlier diagnosis because new therapies are available when we catch people in earlier stages,' Moughamian said. Moughamian is leading two clinical trials that examine whether drugs that remove amyloid in the brain, donanemab and another drug remternetug, can work in people who have amyloid plaques but have not yet developed symptoms. They are using an Alzheimer's blood test to see whether patients are eligible for the trial.
